ArticleNature2012
A vaccine strategy that protects against genital herpes by establishing local memory T cells.
Article in Nature, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 437 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
437 citing papers in PubMed, 624 citations in OpenAlex.
- Combination of live-attenuated and adenovirus-based vaccines provides immediate and durable protection againstMolecular therapy. Nucleic acids · 2026Article
- The Impact of Antigen Presentation on BBB Disruption and Neuroinflammation.Physiology (Bethesda, Md.) · 2026Review
- Interferon-λ inhibits immunopathology and boosts T cell-mediated immunity in a mouse model of mucosal viral infection.The Journal of clinical investigation · 2026Article
- Review
- Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity.EMBO molecular medicine · 2026Article
- Genital Tract and Circulating CD8+ T Cell Phenotypes Vary Across the Menstrual Cycle.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Article
- CCR5 blockade inhibits menstrual-driven proinflammatory T cell infiltration into the cervicovaginal mucosa of women.Science advances · 2026Article
- Epithelial interferon-γ responsiveness shapes chemokine induction and clinical outcomes in herpes simplex virus infection.PLoS pathogens · 2026Article
- Article
- On or within: spatial determinants of antigen handling in the nasal turbinates.Current opinion in immunology · 2026Review
- Tumor-draining lymph nodes shape the tumor microenvironment through enrichment of tumor-reactive effector-exhausted CD8Signal transduction and targeted therapy · 2026Article
- CD8MedComm · 2026Review
- Harnessing mucosal immunity for protective vaccines.Nature reviews. Immunology · 2026Review
- Temporal Dissection of TGF-β signaling reveals differential impact during female reproductive mucosal CD8 resident memory T cell differentiation.Mucosal immunology · 2026Article
- T-Cell Biology in the Female Reproductive Tract: Relevance to HIV Infection.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- An intramuscular prime-intranasal boost strategy for mRNA-LNP vaccine induces mucosal immune response against SARS-CoV-2 in murine model.Journal of translational medicine · 2026Article
- Intranasal boosting enhances genital tract T cell immunity following ChAdOx1/MVA hrHPV therapeutic vaccination.NPJ vaccines · 2026Article
- Flipping the script: Using mucosal immune obstacles to inform vaccine design.PLoS pathogens · 2026Article
- Nasal humoral immunity: the first line of protection against respiratory pathogens.ImmunoHorizons · 2026Review
- Living rent free in your head: resident memory T cells.ImmunoHorizons · 2026Review
377 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Most successful existing vaccines rely on neutralizing antibodies, which may not require specific anatomical localization of B cells. However, efficacious vaccines that rely on T cells for protection have been difficult to develop, as robust systemic memory T-cell responses do not necessarily correlate with host protection. In peripheral sites, tissue-resident memory T cells provide superior protection compared to circulating memory T cells. Here we describe a simple and non-inflammatory vaccine strategy that enables the establishment of a protective memory T-cell pool within peripheral tissue. The female genital tract, which is a portal of entry for sexually transmitted infections, is an immunologically restrictive tissue that prevents entry of activated T cells in the absence of inflammation or infection. To overcome this obstacle, we developed a vaccine strategy that we term 'prime and pull' to establish local tissue-resident memory T cells at a site of potential viral exposure. This approach relies on two steps: conventional parenteral vaccination to elicit systemic T-cell responses (prime), followed by recruitment of activated T cells by means of topical chemokine application to the restrictive genital tract (pull), where such T cells establish a long-term niche and mediate protective immunity. In mice, prime and pull protocol reduces the spread of infectious herpes simplex virus 2 into the sensory neurons and prevents development of clinical disease. These results reveal a promising vaccination strategy against herpes simplex virus 2, and potentially against other sexually transmitted infections such as human immunodeficiency virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.